When it comes to understanding and treating blood cancers, few places offer the depth of expertise and innovative care that Medstar Georgetown University Hospital does. In our latest podcast episode, we had the privilege of speaking with Dr. Kieron Dunleavy, an internationally recognized expert in lymphoma, who sheds light on the complexities and advancements in treating this challenging group of diseases.  

Dr. Dunleavy is the Section Chief of Hematology and Disease Group Lead for Malignant Hematology at Medstar Georgetown University Hospital. His extensive experience and dedication to patient care are evident as he discusses the hospital's comprehensive approach to treating blood cancers such as leukemia, lymphoma, and multiple myeloma. One of the key highlights of our conversation is the multidisciplinary approach employed by Medstar Georgetown, which ensures that patients receive holistic and personalized care.   

Lymphoma, as Dr. Dunleavy explains, is a cancer of the lymphatic system, which can manifest in various ways depending on whether it arises from B cells or T cells. He emphasizes the importance of accurate diagnosis, given the over 100 different types of lymphomas that exist. This precision in diagnosis is crucial as it directly influences the treatment plan and ultimately the patient's prognosis.   

One of the most exciting aspects of our discussion was learning about the cutting-edge treatments being utilized at Medstar Georgetown. Dr. Dunleavy talks about the advent of therapies such as CAR T cells and bispecific antibodies, which have significantly improved outcomes for patients. These therapies are part of a broader trend in oncology to develop treatments that are not only more effective but also less toxic than traditional chemotherapy.   

Clinical trials play a pivotal role in advancing cancer treatment, and Medstar Georgetown is at the forefront of this research. Dr. Dunleavy shares insights into several ongoing trials, including studies on immune checkpoint inhibitors and virus-specific T cells. These trials offer hope for better treatments and potentially higher cure rates for patients with various types of lymphoma.   

For those newly diagnosed with lymphoma or those whose disease has recurred, Dr. Dunleavy stresses the importance of asking the right questions. Ensuring the accuracy of the diagnosis, understanding the available treatment options, and inquiring about clinical trials are all critical steps in the journey toward recovery.   

The future of lymphoma treatment is bright, with ongoing research and new technologies promising to further improve patient outcomes. Liquid biopsies, for instance, are an emerging tool that can provide valuable information about cancer cells from a simple blood draw, potentially transforming how we diagnose and monitor these diseases.   

Dr. Dunleavy's optimism about the future of cancer care is contagious. His dedication to reducing treatment-related toxicity while maintaining high cure rates is a testament to the progress being made in the field of oncology. Listening to this episode will not only inform you about the latest advancements in lymphoma treatment but also inspire hope for a future where cancer is increasingly more manageable and curable.   

Tune in to our latest episode to hear more from Dr. Kieron Dunleavy and stay informed about the latest in cancer research and treatment. Whether you are a patient, a caregiver, or simply interested in medical advancements, this episode is a must-listen.

For an interview with Dr. Dunleavy, or for more information about this podcast, contact MedStar Georgetown University Hospital Manager of Media Relations, Ryan.M.Miller2@Medstar.net.